A pooled analysis by the European Organisation for Research and Treatment of Cancer Receptor and Biomarker Group (EORTC-RBG) used the raw data of most uPA and PAI-1 determinations available at the time worldwide in numerous retrospective and prospective breast cancer studies and confirmed the prognostic value in more than 8,000 patients [2,11,12]. This evidence concerns the gene SERPINE1 and breast cancer.